Trial Profile

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 212Pb VMT alpha NET (Primary)
Indications Carcinoma; Gastrointestinal stromal tumours; Head and neck cancer; Nasopharyngeal cancer; Pancreatic cancer; Paraganglioma; Phaeochromocytoma; Renal cell carcinoma; Small cell lung cancer
Focus Adverse reactions; First in man

24 Aug 2025 Planned initiation date changed from 17 Aug 2025 to 28 Aug 2025.
22 Aug 2025 Status changed from not yet recruiting to recruiting.
12 Aug 2025 Planned initiation date changed from 16 Jul 2025 to 17 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com